Syros Pharmaceuticals (SYRS)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	60.39 mm	60.39 mm	60.39 mm	60.39 mm	60.39 mm	60.39 mm
Cash burn (monthly)	6.90 mm	4.58 mm	8.73 mm	9.30 mm	6.90 mm	8.33 mm
Cash used (since last report)	29.81 mm	19.78 mm	37.73 mm	40.22 mm	29.81 mm	36.03 mm
Cash remaining	30.58 mm	40.61 mm	22.67 mm	20.17 mm	30.58 mm	24.36 mm
Runway (months of cash)	4.4	8.9	2.6	2.2	4.4	2.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SYRS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	73	74	-1.4%
Opened positions	15	10	+50.0%
Closed positions	16	17	-5.9%
Increased positions	11	19	-42.1%
Reduced positions	15	11	+36.4%

13F shares	Current	Prev Q	Change
Total value	39.82 bn	103.46 bn	-61.5%
Total shares	30.74 mm	27.90 mm	+10.2%
Total puts	1.27 mm	3.20 k	+39623.9%
Total calls	208.81 k	21.20 k	+885.0%
Total put/call ratio	6.1	0.2	+3933.1%

Largest owners	Shares	Value	Change
Invus Global Management	3.65 mm	$9.16 mm	NEW
Bain Capital Life Sciences Investors	2.75 mm	$5.91 bn	+0.0%
Bain Capital Life Sciences Fund II	2.75 mm	$6.90 mm	+29.4%
Siren, L.L.C.	2.59 mm	$5.56 bn	NEW
Samsara BioCapital	2.49 mm	$14.41 mm	0.0%
Adage Capital Partners GP, L.L.C.	2.07 mm	$4.45 bn	0.0%
Samsara BioCapital	1.79 mm	$3.84 bn	0.0%
Point72 Asset Management	1.47 mm	$3.16 bn	0.0%
Artal International S.C.A.	1.46 mm	$0.00	0.0%
Ally Bridge MedAlpha Master Fund	1.44 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
Invus Global Management	3.65 mm	+3.65 mm	NEW
Siren, L.L.C.	2.59 mm	+2.59 mm	NEW
Artal	0.00	-2.51 mm	EXIT
Bain Capital Life Sciences Fund II	2.75 mm	+625.46 k	+29.4%
Avidity Partners Management	1.06 mm	-610.54 k	-36.5%
Kennedy Capital Management	0.00	-427.54 k	EXIT
GS The Goldman Sachs Group, Inc.	0.00	-262.37 k	EXIT
BlackRock	261.58 k	+261.58 k	NEW
BLK BlackRock	0.00	-259.19 k	EXIT
Opaleye Management	654.94 k	-210.50 k	-24.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SYRS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
2 Dec 24	Simonian Nancy A	Common Stock	Sell	Dispose S	No	No	0.2702	37,070	10.02 k	4,000
25 Nov 24	Simonian Nancy A	Common Stock	Sell	Dispose S	No	No	0.2653	134,713	35.74 k	41,070
19 Nov 24	Gerald E Quirk	Common Stock	Sell	Dispose S	No	No	0.2212	46,657	10.32 k	0
18 Nov 24	Jason Haas	Common Stock	Sell	Dispose S	No	No	0.2103	137,803	28.98 k	0
18 Nov 24	Kristin Stephens	Common Stock	Sell	Dispose S	No	No	0.22	36,133	7.95 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Syros Pharmaceuticals Gave Notice To Qiagen Manchester Limited Of Its Election To Terminate The Master Collaboration Agreement Dated March 7, 2022

18 Nov 24

On November 13, 2024, Syros Pharmaceuticals, Inc. (the "Company") gave notice to QIAGEN Manchester Limited ("QIAGEN") of its election to terminate the Master Collaboration Agreement dated March 7, 2022 (the "Agreement")

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

13 Nov 24

S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results

13 Nov 24

Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings

13 Nov 24

Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default

13 Nov 24

Press releases

From Benzinga Pro

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

12 Nov 24

-- SELECT-MDS-1 Did Not Meet its Primary Endpoint -- -- Company to Discontinue Study, Review Full Data Set, and Evaluate Next Steps -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to